Investigator(s)
| WHO Technical Officer |
Deyer Gopinath WCO Myanmar Deyer Gopinath 
|
| Principal Investigator |
Dr. Moe Kyaw Myint Mail Parasitology Research Division, Department of Medical Research, Myanmar Dr. Moe Kyaw Myint Mail
|
| Co-Investigator(s) |
Dr. Myat Htut Nyunt Bioinformatics Division, Advanced Molecular Research Center, Department of Medical Research, Myanmar Dr. Myat Htut Nyunt
|
| Co-Investigator(s) |
Dr. Nwe Ni Lin Vector Borne Disease Control Programme, Department of Public Health, Ministry of Health, Myanma Dr. Nwe Ni Lin
|
Title(s) and abstract
| Scientific title | Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for Plasmodium vivax malaria in Nansang Township, Southern-Shan State, Myanmar |
| Public title | Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for Plasmodium vivax malaria in Nansang Township, Southern-Shan State, Myanmar |
| Background | The recommended ACTs for treatment of uncomplicated falciparum malaria in Myanmar are: (a) artemether-lumefantrine (b) dihydroartemisinin-piperaquine combination and (c) artesunate-mefloquine combination Chloroquine is the first line drug for treatment of vivax malaria. All these antimalarials are given free of charge by public health facilities, volunteers in the community and some private clinics/hospitals. Therapeutic efficacy studies (TES) done in 2016 showed that Adequate Clinical and Parasitological Response (ACPR) to artemether-lumefantrine and dihydroartemisinin-piperaquine phosphate were 96.2 % and 100 %, respectively, in Ta Beik Kyin township, Mandalay Region and 98.1 % and 100 %, respectively, in Ta-mu township, Kachin State. In 2017, ACPR of artemether-lumefantrine in Moe Nyin township, Kachin State and Naung Cho, township, Northern Shan State was 93.3% and 93.1%, respectively. In the same sentinel sites, ACPR to pyronaridine-artesunate was 100% in 2017. Similar studies in other sentinel sites showed that ACPR was more than 95 % in the previous years. For vivax malaria, the 2014 and 2015 TES results showed chloroquine efficacy against P. vivax malaria from 96% to 100% i |
| Objectives | To assess the efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for Plasmodium vivax malaria |
| Study Methods | This surveillance study is a one arm prospective evaluation of clinical and parasitological responses to directly observed treatment for uncomplicated malaria. People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, treated on site with artemether-lumefantrine for uncomplicated P. falciparum malaria and chloroquine phosphate for P. vivax and monitored for 28 days. |
| Expected outcomes and use of results | The results of this study will be used to assist the Ministry of Health, Myanmar in assessing the efficacy of drugs in current national treatment guidelines for uncomplicated P. falciparum malaria and for P. vivax malaria and to update the treatment policy, if necessary |
| Keywords | malaria,Therapeutic efficacy |
Research Details
| Student research | No |
| Start Date | 01-Apr-2025 |
| End Date | 31-Mar-2026 |
| Key Implementing Institution | World Health Organization |
| Multi-country research | No |
| Nationwide research | No |
| Myanmar | |
| Research Domain(s) | Communicable Disease Research |
| Research field(s) | Malaria |
| Involves human subjects | Yes |
| Clinical Trial with Human Subjects | |
| Data Collection | Primary and secondary data |
| Proposal reviewed by other Committee | Final decision available |